This study sought to investigate the prevalence of programmed death ligand 1 (PD-L1) and its prognostic value in patients with residual tumors after neoadjuvant chemotherapy (NCT) for locally advanced breast cancer. A total of 309 patients considered as non-pathological complete responders (non-pCR) after NCT followed by mastectomy were selected. The expression of PD-L1 and tumor-infiltrating lymphocytes (TILs) in residual breast cancer cells was assessed by immunohistochemistry in surgical specimens. The median density was used to classify PD-L1 expression from low to high. The prognostic value of various clinicopathological factors was evaluated. The expression of PD-L1 was more commonly observed in patients with low levels of total TILs (p < 0.001), high levels of FOXP31 TILs (p < 0.001) and low levels of CD81 TILs (p < 0.001). This served as an independent prognostic factor for both relapse-free survival (Hazard ratio 5 1.824, p 5 0.013) and overall survival (OS) (Hazard ratio 5 2.585, p 5 0.001). High expression of PD-L1 was correlated to worse survival, which is most significantly observed in triple-negative patients. Patients classified as PD-L1-high/CD8-low exhibited relatively unfavorable survival, whereas patients with either low expression of PD-L1 or high expression of CD8 had similar outcomes. PD-L1 expression in residual tumor can be used as a prognostic marker in non-pCR patients after receiving NCT for breast cancer, which highlights the importance of immune evasion in the therapeutic vulnerability of chemoresistant cancer cells as well as the potential of anti-PD-L1 treatments in non-pCR responders.
Neoadjuvant chemotherapy (NCT) followed by definitive surgical therapy is the gold standard of care for locally advanced breast cancer. A pathologically complete response (pCR) after neoadjuvant therapy is an indicator of excellent survival. However, patients with residual invasive disease may have relatively unfavorable outcomes. [1] [2] [3] One previous study indicated that residual cancer cells remaining after chemotherapy may have decreased sensitivity to additional systemic treatment and more aggressive behavior that promotes metastasis. 4 Because most patients fail to achieve pCR, a practical prognostic marker is needed to identify high-risk patients and select candidates for further individualized treatment. Recently, the tumor immune microenvironment has generated growing interest given its predictive and prognostic value in breast cancer. Programmed death ligand 1 (PD-L1) is a transmembrane protein belonging to the B7 family of immune molecules. It has been shown to play an essential role in limiting the cytotoxic immune response via interaction with the programmed death-1 (PD-1) receptor. 5 The PD-L1/PD-1 axis helps to reduce the cellular immune response by inducing T cell tolerance, which may result in preventing autoimmunity in certain organs and promote tumor regression. [5] [6] [7] PD-L1 expression has been noted in a variety of solid tumor types, including lung, melanoma and breast. 5, 8, 9 It has been reported that PD-L1 expression in breast cancer is significantly enriched in basal-like tumors and highly proliferative tumors and is correlated to the presence of tumor-infiltrating lymphocytes (TIL). 9, 10 TILs have been reported to be a reliable marker of chemotherapy efficacy and have been associated with clinical outcomes in breast cancer. [11] [12] [13] Recent studies have suggested that different subtypes of TILs may play different roles; for instance, cytotoxic T cells (CD81 T cells) are associated with improved clinical outcomes, 14, 15 whereas regulatory T cells defined as forkhead box protein 3 (FOXP3)1 T cells play a pivotal role in suppressing antitumor immunity. 15, 16 Although the prevalence of PD-L1 expression is closely correlated to TILs, its clinical value is merely acknowledged. Some have reported that the PD-L1 expression level, together with TILs, can predict responsiveness to NCT independent of tumor localization and treatment. 17 However, other studies that addressed the prognostic capabilities reported divergent results, 10, 18, 19 suggesting that PD-L1 may have a dual functions in antitumor immune response.
In this study, we investigate the prevalence and prognostic value of PD-L1 together with either CD81 or FOXP31 TILs in residual tumors following NCT comprising various regimens. The aim of our study was to further clarify the relationship between PD-L1 and TILs and to identify reliable markers for the appropriate selection of high-risk patients eligible for more aggressive therapeutic agents. To our knowledge, this is the first study to demonstrate the prognostic role of PD-L1 in residual breast cancer cells after chemotherapy.
Patient and Methods

Study population
We retrospectively collected data and surgical specimens from 448 consecutive patients who underwent NCT following radical surgery at Shanghai Cancer Center from 2003 to 2010. All of the included patients were diagnosed with local advanced breast cancer (T3/T4 and/or N2/N3 stages). Blood chemistry, bone scan, chest X-ray and abdominal ultrasound examination were performed to exclude metastatic disease before the initiation of NCT. The disease state of all included patients was confirmed as invasive carcinoma using a core needle biopsy (CNB), and fine needle aspiration of either palpable or ultrasound-detected lymph nodes was performed at the time of diagnosis. Patients with bilateral breast cancer, male breast cancer or inflammatory breast cancer were not included in this study. Among the included patents, 21.2% (95) of patients achieved pCR and the primary tumor samples of 44 patients were either insufficient or unavailable for IHC staining. Therefore, 309 patients with residual invasive disease after NCT were included in this study. . No other anticancer treatments, including chemotherapy, radiation therapy or endocrine therapy before surgery, were permitted. After completion of NCT, all of the patients underwent mastectomy and axillary lymph node dissection within four weeks. Subsequently, additional cycles of chemotherapy were administered after the operation to complete a total of 6 cycles at the discretion of the treating physician. The use of radiation therapy was at the discretion of the treating radiologist and was based on the disease status prior to NCT. Endocrine therapy was administered to hormone receptor-positive patients. Trastuzumab was not included in any pre-operative treatment; however, it was recommended for human epidermal receptor-2 (HER-2) 1 patients in the adjuvant setting.
Pathological evaluation
The pathological evaluation of biopsy and surgical specimens was conducted at the Shanghai Cancer Hospital Pathology Center by two experienced pathologists. All of the patients in this study were confirmed to have residual invasive ductal carcinoma in the breast after NCT following pathological evaluation of the surgical specimens. The Miller-Payne (MP) grading system was used to evaluate the pathological response 20 ; either no change or some alteration to individual malignant cells but no reduction in overall cellularity was classified as grade 1; up to a 30% loss of tumor cells was classified as grade 2; an estimated 30-90% reduction in tumor cells was classified as grade 3; >90% loss of tumor cells such that only small clusters or widely dispersed individual cells remained was classified as grade 4; and no remaining invasive malignant cells was classified as grade 5.
Expression of the estrogen receptor (ER), the progesterone receptor (PR) and HER-2 were collected from a database from the pathological center at Shanghai Cancer Hospital. The cut-off value for ER positivity and PR positivity was 1% of tumor cells with positive nuclear staining. The HER-2 positive status was
The presence of residual cancer cells following neoadjuvant therapy for locally advanced breast cancer greatly increases the risk of disease recurrence. It may be possible, however, to identify patients at high risk of recurrence and thereby facilitate treatment decisions by evaluating the expression of programmed death ligand 1 (PD-L1). Here, among breast cancer patients who underwent neoadjuvant therapy but failed to achieve a pathologic complete response, high PD-L1 expression was associated with poor survival, particularly for tumors lacking CD81 tumor-infiltrating lymphocytes and triple-negative breast cancers. The study of PD-L1 further sheds light on immune evasion in chemoresistant breast cancer.
defined as 31 according to either circumferential membranebound staining [HercepTest (Dako Cytomation, Carpinteria, CA)] or amplification confirmed by fluorescent in situ hybridization. According to the 2011 St. Gallen consensus, 21 breast cancer subtypes were defined as follows: luminal A (ER and/or PR positive, HER-2 negative and Ki-67 <15%); luminal B (ER and/or PR positive, HER-2 positive; ER and/or PR positive, HER-2 negative and Ki-67 15%); HER-21 (ER and PR negative, HER-2 positive) or triple negative (TNBC; ER negative, PR negative and HER-2 negative).
Immunohistochemistry (IHC)
IHC was performed on formalin-fixed, paraffin-embedded tissue sections collected from residual tumor specimens using a 2-step protocol (GTVision TM III). PD-L1 was detected using the rabbit anti-PD-L1 polyclonal antibody ab205921 (Abcam). FOXP3 was detected using the rabbit anti-FOXP3 polyclonal antibody ab54501 (Abcam). CD8 was detected using the rabbit anti-CD8 polyclonal antibody ab4055 (Abcam). Ki-67 was detected using the mouse monoclonal antibody MIB-1 (Dako). Negative control samples were treated identically but without the addition of primary antibodies. Positive control samples were developed based on the antibody instruction.
Ki-67 expression was evaluated independently by two experienced pathologists on a case-by-case basis and expressed as the percentage of positive cells (at least 1,000) with nuclear staining. The density of positive staining for PD-L1 on residual tumor cells was measured using a computerized image system composed of a Leica CCD camera DFC420 connected to a Leica DM IRE2 microscope (Leica Microsystems Imaging Solutions, Cambridge, United Kingdom). Photographs of 10 representative fields were captured using the Leica QW Plus v3 software. A uniform setting was applied for all slides to assess the expression of PD-L1. The integrated optical density (IOD) of all positive stainings in each photograph was measured, and its ratio over the total area of each photograph was defined as the PD-L1 density. The density was calculated using Image-Pro Plus v6.2 software (Media Cybernetics) as previously described. 22, 23 The assessment of unstained TILs was based on the recommendations by an International TIL Working Group. 24 TILs were evaluated within the stromal compartment close to the invasive tumor and reported as the percentage of stromal TILs. The number of CD81 or FOXP31 TILs was measured within the stromal areas of the tumor under high-power magnification (4003) for each case, and the mean number of CD81 or FOXP31 lymphocytes per high power field (HPF) was counted.
Statistical analysis
The v 2 test was used to evaluate the relationship between the variables. The Fisher's exact test was performed when necessary. The quantitative variables were analyzed with Student's t test (a paired sample t test was used when needed).
Relapse-free survival (RFS) was calculated from the date of surgery to the date of disease relapse (defined as local or distant relapse or death from any cause). Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. Patients who had not experienced either events or death were censored at the last follow-up. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was used to test for differences between the groups. All of the reported p-values were two sided, and p values <0.05 were considered to be statistically significant. All analyses were performed using SPSS (version 13.0, SPSS Company, Chicago, IL).
Results
IHC detection of PD-L1 and TILs
Positive staining for PD-L1 protein was observed mainly in the cytoplasm of residual cancer cells (Figs. 1a-1d). The median density for PD-L1 protein was 0.022 (range: 0.001-0.137). Of the tested patients, 156 had a PD-L1 density of 0.001-0.022, which was defined as low density, whereas 153 had a PD-L1 density >0.022, which was defined as high density. We also measured the percentage of positive cells with any PD-L1 staining intensity in all the patients. All the patients in low density group have positive cells under 8%. Majority of patients in high density group have positive cells over 10%, whereas 14 patients are of between 5 and 10%. To investigate the heterogeneity of PD-L1 distribution, we classified the positively stained cells as either central tumor cells (i.e., from the tumor center to the midpoint the tumor margin) or extratumoral cells (normal cells outside of the tumor; Supporting Information Figure S1A ). The peripheral and central areas of tumor shared a uniform distribution of PD-L1; however, the density was significantly lower in the extratumoral area (p < 0.001). TILs in the stromal area of the tumor bed were counted according to the recommendations by an International TIL Working Group, 24 whereas TILs outside of the tumor border were excluded (Supporting Information Figure S1B ). The cutoffs for high or low infiltration were defined as having the median number of infiltrating cells per field as follows: CD81 TILs, 70 infiltrating cells per field; FOXP31 TILs, 30 infiltrating cells per field. The patients were classified into the high TIL group with the recommended cutoff of 50%.
Patient characteristics and PD-L1 expression
There were 309 patients with residual invasive disease after NCT included in this study. The median age was 49 years, and 58.6% of patients were pre-menopausal. Approximately 16.2% of patients underwent CEF as a NCT regimen, whereas 38.8% underwent NE and 45.0% underwent PC. According to the MP grading system, 29 patients experienced near pCR (MP4), 163 patients experienced partial response (MP3) and 117 patients experienced unfavorable response (MP2/1).
Based on the ER, PR, HER-2 and Ki-67 statuses, patients were classified into the following subtypes: luminal A (24.6%), luminal B (33.3%), HER-21 (15.2%) and TNBC (26.9%). The relationship between PD-L1 expression and the patients' demographic characteristics is shown in Table 1 . Most of the clinical and pathological features did not correlate to PD-L1 expression. However, a high PD-L1 density was more commonly observed in patients with low level of total TILs (p < 0.001), a high level of FOXP31 TILs (p < 0.001) and a low level of CD81 TILs (p < 0.001). The exact number of TILs according to PD-L1 expression is shown in Figure 2 , and similar trend was observed in that a higher mean value of CD81 TILs and lower mean value of FOXP31 TILs was related to low PD-L1 density. 
Survival analysis
The median follow-up time was 70 months. The 5-year RFS and OS rates of all of the patients were 69.6 and 78.4%, respectively. Univariate and multivariate survival analyses were performed to determine the association between the patient prognosis and variables ( 2 Definition of breast cancer subtypes: luminal A (ER and/or PR positive, HER-2 negative and Ki-67 < 15%), luminal B (ER and/or PR positive, HER-2 positive/ER and/or PR positive, HER-2 negative and Ki-67 15%), HER-21 (ER and PR negative, HER-2 positive) and triple negative (ER negative, PR negative and HER-2 negative).
Using a combination of PD-L1 and CD8 expression, all of the patients were classified into the following four subgroups: PD-L1-low/CD8-low (n 5 53); PD-L1-high/CD8-low (n 5 102); PD-L1-low/CD8-high (n 5 103); and PD-L1-high/CD8-high (n 5 51). The survival curves of these 4 groups are shown in Figures 3e and 3f . The prognostic value of PD-L1 was significant in CD8-low patients (p 5 0.011 for RFS and p 5 0.029 for OS), but not in CD8-high patients (p 5 0.495 for RFS and p 5 0.279 for OS). In fact, patients classified as PD-L1-high/ CD8-low had a relatively unfavorable outcome for the 5-year RFS (54%) and 5-year OS (67%), whereas the other three groups had similar outcomes with an 5-year RFS of 75-82% and an 5-year OS of 80-88%.
We also analyzed the relationship between PD-L1 expression and survival according to different breast cancer subtypes (Supporting Information Figure S2 ). Among the four subtypes, the prognostic value of PD-L1 was most significant among TNBC patients for both RFS and OS (p < 0.001; survival curves shown in Fig. 4) . PD-L1 expression was capable of differentiating between low-risk and high-risk TNBC patients with 5-year RFS values of 89 and 45%, respectively, and 5-year OS values of 91 and 51%, respectively.
Discussion
The myriad of genetic and epigenetic alterations that are characteristic of all cancers provide various sets of antigens that the immune system can distinguish from normal cells, thereby requiring tumors to develop specific immune evasion mechanisms. 25 The PD-L1/PD-1 axis is one of the most wellknown immune check points that helps reduce the cellular immune response by inducing T cell tolerance to prevent autoimmunity in specific organs and promote tumor regression. [5] [6] [7] By upregulating PD-L1 expression on the surface membrane, cancer cells can inhibit the immune reaction via binding to PD-1 presented on T cells. This reaction might play a pivotal role in the chemo-resistant mechanism. There is an emerging concept that the cancer therapy response is at least partially dependent on an immunological reaction against tumor cells that are dying during chemotherapy. 26 In breast cancer, the intensity of tumoral immune response, as represented by presence of TILs, influences the effectiveness of chemotherapy and is correlated with a better response and more favorable clinical outcome. 27, 28 Although some studies have suggested that PD-L1 might help to predict the possibility of pCR, 29 the prognostic value of PD-L1 has been scarcely reported in a neoadjuvant setting.
NCT, which is also known as preoperative, primary or induction chemotherapy, is the gold standard of care for local advanced breast cancer. After NCT, the majority of patients with residual disease have a relatively higher risk of relapse and death even if they receive additional systemic therapy, and the biological features of these chemo-resistant cancer cells have drawn significant attention in recent studies. In this study, we focused on the prevalence and significance of PD-L1 protein expression in residual breast cancer cells after NCT. PD-L1 expression was not affected by the patients' age; menopausal status; tumor size; node involvement and tumor subtype based on ER, PR, HER-2 and Ki-67 expression. In the multivariate survival analysis, PD-L1 expression was an independent prognostic value for both RFS and OS. Because the treatment regimen, treatment cycle and treatment response (evaluated in this study according to MP grading) were not correlated with patient survival, our findings provide evidence that cancer cells expressing high levels of PD-L1 might have an increased ability to avoid immune clearance, which can result in a worse outcome. We also analyzed the relationship between PD-L1 and TILs. TILs have been reported to differ among breast cancer subtypes and are considered to be a reliable marker of the efficacy of either chemotherapy or trastuzumab, especially in the TNBC and HER2-enriched subtypes. Some studies demonstrate a positive relationship between PD-L1 and TILs 17 ; however, we have opposite results. This is possibly due to different microenvironment before and after chemotherapy, and the different cut-off methods to detect PD-L1 positivity. It is suggested that the subclassification of TILs is pivotal; CD81 T cells have been reported to be associated with improved outcomes whereas FOXP31 T cells are considered to play a pivotal role in immune suppression. Many studies have suggested that the expression of PD-L1 was associated with infiltrating lymphocytes, 10, 30 and either reduced CD81 lymphocyte infiltration 31 or increased FOXP31 lymphocyte infiltration 32, 33 was related to elevated PD-L1 expression in breast cancer. However, most of these studies are based on primary tumors without treatment. In this study, we also observed a close relationship between PD-L1 and TILs identified as either CD81 or FOXP31 among the residual chemoresistant cells. An elevated PD-L1 density was more commonly observed in patients with low levels of total TILs, high levels of FOXP31 TILs and low levels of CD81 TILs. Furthermore, number of infiltrating CD81 TILs was associated with patient outcome, but either the total number of TILs or FOXP31 TILs failed to show any prognostic value. Remarkably, only patients classified as PD-L1-high/CD8-low exhibited a relatively lower RFS and OS whereas patients with either low PD-L1 or high CD8 shared a similar outcome. This finding indicated a synergistic effect of the presence of PD-L1 on tumor cells and the absence of cytotoxic T cells in the tumor immune microenvironment. Based on the limited data on the detailed subclassification of TILs as either CD81 or FOXP31 TILs, studies evaluating the association of the CD81 TIL or FOXP31 TIL status with clinical outcome have reported conflicting findings.
14,34-36 Because PD-L1 was scarcely included in these analyses, it is plausible that the role of TILs in immune evasion was effected by PD-L1 expression on cancer cells.
A recent study reported that PD-L1 expression in both immune and tumor cells is rare and significantly enriched in basal-like tumors. 10 In this study, although we did not find differences in PD-L1 expression regarding the tumor subtype, it is interesting that the prognostic value of PD-L1 was most significant in TNBCs for both RFS and OS. TNBC is a biological entity that lacks ER, PR and HER-2 expression. It is widely believed that TNBC is initially chemosensitive to NCT; however, non-pCR patients with residual TNBC generally have a high risk of relapse and death. 37 Recent studies mainly focused on the classification and identification of subgroups of TNBC, [38] [39] [40] [41] which may help to distinguish between highly aggressive and less aggressive TNBC clones. Our study has introduced the notion that the immune environment may help to differentiate TNBC patients with regard to survival; furthermore, because residual cancer cells after NCT usually remain chemo-resistant to subsequent chemotherapies, new strategies involving the inhibition of the immune evasion mechanism might succeed. Recently, several earlyphase clinical trials using anti-PD-1 strategies have demonstrated favorable objective responses in patients with various types of advanced cancer. 42 In breast cancer, a phase Ib trial (KEYNOTE-012) described preliminary evidence of clinical activity and a potentially acceptable safety profile of the anti-PD-L1 antibody pembrolizumab in patients with heavily pretreated, advanced TNBC. 43 Considering our findings, it is plausible to consider that patients with high expression levels One primary concern of this study is the methodology of detecting PD-L1. Although IHC staining is widely used throughout the literature, the testing protocol and antibodies varies and definition of a "positive" PD-L1 staining is still conflicting. In some study, the PD-L1 positivity are defined as percentage of positive staining cells 44 ; whereas others used the score system 17 regarding staining intensity. In this study, we use the IOD of all positive stainings in each photograph in order to include both quantity and intensity. We also measured the percentage of positive cells with any PD-L1 staining intensity in all the patients and found a favorable accordance with our method. Although the methodology of detecting PD-L1 still need to be validated for future practice, it is plausible in this preliminary study to identify the residual cells expressed high level of PD-L1. Furthermore, there are still considerable gaps in our knowledge regarding the technical aspects of the IHC test and the biological implications and associations of PD-L1 expression, including expression heterogeneity, dynamic changes in expression and prognostic implications. 45 Based on a sufficient sampling of the excised specimens of shrunken tumors, it is possible to obtain accurate information concerning the level of PD-L1 in the residual tumor from this study. Additionally, we did not find heterogeneity in the intratumoral distribution of PD-L1, which indicates that it may serve as a reliable marker in residual tumors after NCT. However, it is important to note that we were unable to obtain information regarding PD-L1 expression prior to NCT. In fact, the heterogeneity of expression and insufficient sampling of CNB specimens have limited the prognostic impact of PD-L1 and TILs expression prior to treatment in a neoadjuvant setting. Furthermore, we used a quantitative method of measuring PD-L1 density, which made our cutoff value more reliable and reasonable.
Conclusion
In conclusion, the current study highlighted the utility of IHC staining of PD-L1 and established this as a potential prognostic marker in non-pCR patients after NCT, especially in residual tumors lacking CD81 TILs and in TNBCs. Moreover, our findings may lead to further understanding of the importance of immune checkpoints in the therapeutic vulnerability of chemo-resistant cancer cells. Thus, PD-L1 and its correlated TILs may help shape postoperative treatment strategies for the prevention of disease relapse in non-pCR patients. It is also plausible to conceive of clinical trials employing an anti-PD-L1 regimen as a follow-up treatment in non-pCR responders.
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Translational Relevance
To our knowledge, this is the first study to demonstrate the prognostic role of PD-L1 in residual breast cancer cells after chemotherapy. Our study has highlighted the utility of PD-L1 staining as a prognostic marker in non-pCR patients. Moreover, our findings may lead to further understanding of immune evasion in the therapeutic vulnerability of chemoresistant cancer cells as well as the potential of anti-PD-L1 treatment.
